Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer

Open access
Widschwendter, Martin, Zikan, Michal, Wahl, Benjamin, Lempiäinen, Harri, Paprotka, Tobias, Evans, Iona, Jones, Allison, Ghazali, Shohreh, Reisel, Daniel, Eichner, Johannes, Rujan, Tamas, Yang, Zhen, Teschendorff, Andrew E., Ryan, Andy, Cibula, David, Menon, Usha, Wittenberger, Timo·2017·Genome Medicine

Abstract

BACKGROUND: Despite a myriad of attempts in the last three decades to diagnose ovarian cancer (OC) earlier, this clinical aim still remains a significant challenge. Aberrant methylation patterns of linked CpGs analyzed in DNA fragments shed by cancers into the bloodstream (i.e. cell-free DNA) can provide highly specific signals indicating cancer presence. METHODS: We analyzed 699 cancerous and non-cancerous tissues using a methylation array or reduced representation bisulfite sequencing to discover the most specific OC methylation patterns. A three-DNA-methylation-serum-marker panel was developed using targeted ultra-high coverage bisulfite sequencing in 151 women and validated in 250 women with various conditions, particularly in those associated with high CA125 levels (endometriosis and other benign pelvic masses), serial samples from 25 patients undergoing neoadjuvant chemotherapy, and a nested case control study of 172 UKCTOCS control arm participants which included serum samples up to two years before OC diagnosis. RESULTS: The cell-free DNA amount and average fragment size in the serum samples was up to ten times higher than average published values (based on samples that were immediately processed) due to leakage of DNA from white blood cells owing to delayed time to serum separation. Despite this, the marker panel discriminated high grade serous OC patients from healthy women or patients with a benign pelvic mass with specificity/sensitivity of 90.7% (95% confidence interval [CI] = 84.3-94.8%) and 41.4% (95% CI = 24.1-60.9%), respectively. Levels of all three markers plummeted after exposure to chemotherapy and correctly identified 78% and 86% responders and non-responders (Fisher's exact test, p = 0.04), respectively, which was superior to a CA125 cut-off of 35 IU/mL (20% and 75%). 57.9% (95% CI 34.0-78.9%) of women who developed OC within two years of sample collection were identified with a specificity of 88.1% (95% CI = 77.3-94.3%). Sensitivity and specificity improved further when specifically analyzing CA125 negative samples only (63.6% and 87.5%, respectively). CONCLUSIONS: Our data suggest that DNA methylation patterns in cell-free DNA have the potential to detect a proportion of OCs up to two years in advance of diagnosis and may potentially guide personalized treatment. The prospective use of novel collection vials, which stabilize blood cells and reduce background DNA contamination in serum/plasma samples, will facilitate clinical implementation of liquid biopsy analyses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-017-0500-7

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 172

Metadata

Authors
Widschwendter, M., Zikan, M., Wahl, B., Lempiäinen, H., Paprotka, T., Evans, I., Jones, A., Ghazali, S., Reisel, D., Eichner, J., Rujan, T., Yang, Z., Teschendorff, A. E., Ryan, A., Cibula, D., Menon, U., & Wittenberger, T.
Venue
Genome Medicine
Published
2017-12
Volume
9
Issue
1
Pages
116-116
ISSN
1756-994X (ISSN-L)
OpenAlex
W2777534716
Cited by
172
References
6
FWCI
14.33
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. https://app.cochat.ai/papers/10.1186/s13073-017-0500-7
The paper
Widschwendter, M., Zikan, M., Wahl, B., Lempiäinen, H., Paprotka, T., Evans, I., Jones, A., Ghazali, S., Reisel, D., Eichner, J., Rujan, T., Yang, Z., Teschendorff, A. E., Ryan, A., Cibula, D., Menon, U., & Wittenberger, T. (2017). The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Medicine. https://doi.org/10.1186/s13073-017-0500-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.